Heart transplant clinical trial opens
Heart transplant clinical trial opens University of Minnesota serves as a site for an open trial evaluating an organ preservation system that shows promise in making more donor hearts available to transplant patients. University of Minnesota Medical Center is 1 of only 8 locations enrolling eligible heart transplant patients in the International EXPAND Heart Pivotal Trial (NCT02323321). The trials tests the organ care system Heart OCS (TransMedics), which relies on extracorporeal membrane oxygenation to preserve hearts for transplant. Unlike traditional methods of preservation, the system keeps the heart warm and beating outside of the body before transfer to a patient awaiting transplant. In the earlier PROCEED II trial, the system was found to be equivalent to standard cold storage of organs before transplant. University of Minnesota Health Heart Care cardiothoracic surgeon Kenneth K. Liao, MD, PhD, serves as principal investigator.
Transplant surgeons join M Health Heart Care team
University of Minnesota Health welcomes cardiothoracic surgeons Andrew Shaffer, MD, MS, and Matthew Soule, MD, to the Heart Care team. Shaffer has expertise in cardiac and aortic surgery, transplant, and mechanical circulatory support. He completed his residency at Beaumont Health Systems, Oakland University. Soule, who pursued his residency at Dartmouth Hitchcock Medical Center, also has a specialization in lung transplantation. Each completed fellowship training in cardiothoracic surgery at the University of Minnesota.
Trial of LVAD now enrolling
A clinical trial designed to further evaluate the safety and efficacy of HeartMate 3 (St. Jude Medical) as a treatment for advanced left ventricle heart failure is now available through University of Minnesota Medical Center. The multisite clinical trial Momentum 3 Continued Access Protocol is open to patients eligible to receive the recently FDA-approved left ventricular assist device. The trial is a continuation of the Momentum 3 study that first established the device’s utility as a destination therapy for patients with advanced heart failure who are not eligible for a transplant. University of Minnesota Health surgeon Ranjit John, MD, serves as the site’s principal investigator. For information, contact email@example.com.
Left ventricular assist devices have emerged as a viable heart-failure treatment or bridge to transplant. The latest LVADs seek to reduce the risk of thrombosis and further improve outcomes.Continue reading
A patient with heart failure and complex, co-occurring conditions enters a clinical trial and receives an LVAD as a bridge to further therapy. At 2 years post-treatments, he is free of heart-failure symptoms.Continue reading